氨酰心安缓释片治疗轻中度原发性高血压的临床研究

目的观察68例长效心脏选择性B。一肾上腺素受体阻滞剂氨酰心安缓释片治疗轻中度原发性高血压的临床疗效。方法68例轻中度原发性高血压患者服用氨酰心安缓释片25～50mg／d，12周。治疗前后测量坐位血压，监测肝肾功能、血糖、血脂，记录药物不良反应。结果治疗12周后，收缩压和舒张压分别下降（31．50±12．75）mmHg和（17．60±6．45）mmHg（P〈0．05），62例患者血压〈140／90mmHg，降压达标率为91．1％。心率、肝功能和血糖、血脂指标治疗前后差异无统计学意义。血肌酐显著下降（112．63±6．87）μmol／Lvs．（75．32±5．43）μmol／L（P〈0．05.结论氨酰心安缓释片能有效治疗轻中度原发性高血压，无明显不良反应，患者依从性良好。

Clinical Study of Extended Release Atenolol in Treatment of Patients with Mild to Moderate Primary Hypertension

Objective To observe the efficacy and safety of extended release Atenolol in treatment of patients with mild to moderate primary hypertension. Methods 68 patients of mild to moderate primary hypertension were given 25-50 mg/d extended release Atenolol for 12 weeks. Blood pressure, renal function, hepatic function, blood glucose and lipid were measured, and adverse events were recorded before and after treatment. Results After treatment, systolic and diastolic blood pressure were decreased by （31.50 ± 12.75）mmHg and （17.60±6.45）mmHg respectively （P〈 0.05）. There were 86.7% patients with blood pressure less than 140/90mmHg. Heart rate, hepatic function, blood glucose and lipid did not change significantly before and after treatment. However, serum creatinine level reduced significantly after treatment compared with before （112.63 ±6.87μmol/L vs. 75.32 ±5.43μmol/L,P 〈 0.05）. Conclusion Etended release atenololcan effectively treat the patients of mild to moderate primary hypertension with good compliance and no obvious adverse events.